We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria (PRIORITY)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2014 by Peter Rossing, Steno Diabetes Center.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT02040441
First Posted: January 20, 2014
Last Update Posted: February 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Mosaiques Diagnostics GmbH
University Medical Center Groningen
University of Glasgow
Istituto Di Ricerche Farmacologiche Mario Negri
Univerzita Karlova v Praze
Charite University, Berlin, Germany
Geniko Nosokomeio Athinas Ippokrateio
Institut Klinické a Experimentální Mediciny Praze
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Institut Universitaire de Recherche Clinique Montpellier
Klinikum St. Georg Leipzig
Universitaet Zürich
Cyril and Methodius University in Skopje
Hannover Clinical Trial Center
European Commission
Information provided by (Responsible Party):
Peter Rossing, Steno Diabetes Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):